ImmuCell Corporation
ICCC
$9.77
-$0.15-1.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -30.62% | 35.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.62% | 35.82% | |||
| Cost of Revenue | -16.68% | 20.87% | |||
| Gross Profit | -47.67% | 60.04% | |||
| SG&A Expenses | 0.51% | 68.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.40% | 21.85% | |||
| Operating Income | -1.75% | 165.40% | |||
| Income Before Tax | -3.76% | 168.67% | |||
| Income Tax Expenses | 268.00% | 278.79% | |||
| Earnings from Continuing Operations | -5.51% | 168.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.51% | 168.15% | |||
| EBIT | -1.75% | 165.40% | |||
| EBITDA | -3.68% | 72.44% | |||
| EPS Basic | -5.68% | 168.13% | |||
| Normalized Basic EPS | -3.71% | 192.19% | |||
| EPS Diluted | -4.76% | 166.67% | |||
| Normalized Diluted EPS | -5.05% | 196.70% | |||
| Average Basic Shares Outstanding | 0.21% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.58% | -1.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||